Oppenheimer Initiates Compugen(CGEN.US) With Buy Rating, Announces Target Price $4
Compugen Initiated With an Outperform at Oppenheimer
Oppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)
Compugen Says First Patient Dosed in Phase 1 Trial of COM503
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
The Past Five Years for Compugen (NASDAQ:CGEN) Investors Has Not Been Profitable
Ezkilz : no news is moving any share?
Jaguar8 OP Ezkilz : It’s a red day because of the Fed report
Ezkilz Jaguar8 OP : ok i got some jspr, how do i check cash on hand?
Jaguar8 OP Ezkilz : Dilution tracker